Fiscal Year: January - December
Moderna, Inc. (MRNA), listed on the NASDAQ, has a market capitalization of $33.42B. As of May 21, 2025, the stock is trading at $27.99 per share, offering investors a clear view of its current market value. Moderna, Inc. is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of N/A , investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Moderna, Inc. also offers a dividend yield of N/A , making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Moderna, Inc. (MRNA) may be overvalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for Moderna, Inc. is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Moderna, Inc., Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Moderna, Inc. is 0, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Moderna, Inc. (MRNA) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Moderna, Inc. (MRNA) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be overvalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Moderna, Inc. (MRNA) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Moderna, Inc.. To access the full SS Score, consider upgrading your subscription.
Moderna, Inc. is a significant player in the industry sector, with a market capitalization of $33.42B and a competitive P/E ratio of N/A . Investors should compare these metrics with industry peers to gauge whether Moderna, Inc. is outperforming or underperforming within its sector.
U.S. equities were lower at midday, dragged by tech and travel stocks. The Dow Jones Industrial Average, S&P 500, and Nasdaq were all lower.
Moderna's share price has collapsed from $500 to $25, but I believe the selloff is overdone, and the stock is deeply oversold. Short squeeze potential, a robust pipeline, and long-term mRNA/AI opportu...
S&P 500 and Nasdaq edge higher mid-session as weak sentiment data tempers gains. Traders assess inflation risks and tariff uncertainty.
The vaccine maker, which has partnered with OpenAI since 2023, is rethinking how it does workforce planning thanks to the growing capabilities of AI and other tech.
CAMBRIDGE, MA / ACCESS Newswire / May 8, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference: Bernstein's 41st Annual Strategic Decision...
Moderna's Q1 earnings reveal a significant revenue decline and high cash burn, driven by reduced demand for its COVID-19 vaccine and inventory write-downs. Regulatory setbacks for Moderna's combinatio...
Moderna Inc. MRNA reported on Thursday a first-quarter EPS loss of $(2.52), missing the consensus of $(3.12), down from an EPS loss of $(3.07) a year ago.
Moderna, Inc. (NASDAQ:MRNA) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Lavina Talukdar - Senior Vice President, Investor Relations Stephane Bancel - Chief Executive ...
Moderna logged a first-quarter loss as revenue fell, dragged down by lower product sales, though the company said it expects demand to increase during cold and flu season later this year.
Moderna on Thursday reported first-quarter profit and sales that beat Wall Street estimates, helped by the company's cost-cutting efforts following waning post-pandemic demand for its COVID-19 vaccine...
Reports first quarter revenues of $0.1 billion, GAAP net loss of $(1.0) billion and GAAP EPS of $(2.52) Reiterates 2025 expected revenue range of $1.5 to $2.5 billion and 2025 year-end cash balance of...
Moderna shares are down more than 30% this year, and around 75% over the past 12 months.
Analysts say these S&P 500 stocks have at least 50% price upside over the next year or so.
CAMBRIDGE, MA / ACCESS Newswire / April 10, 2025 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 1, 2025 to report ...
CAMBRIDGE, MA / ACCESS Newswire / April 7, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present research across multiple infectious disease areas, including COVID-19, influ...
Major pharmaceutical companies reap most of their profits in the U.S. but shift their tax burdens to low-tax havens such as Ireland.
Major U.S. equities indexes were mixed to kick off the new trading week as U.S. trade policy remained in focus.
Investors were nervous about US President Donald Trump's tariff plans, which caused the S&P 500 to fall on Monday and enter correction territory. However, the index recovered its losses from earlier ...
Stocks of major vaccine makers dropped on Monday after the Food and Drug Administration's (FDA) top vaccine official Dr. Peter Marks resigned, citing conflicts with Health and Human Services (HHS) Sec...
Biotech investors are grappling with fresh uncertainty following the abrupt resignation of Dr. Peter Marks, a key figure in the US Food and Drug Administration.
Shares of vaccine makers Moderna and Novavax, along with a range of other biotech companies, fell after the resignation of key FDA official Peter Marks. Marks stepped down in protest of Health and Hum...
Shares of U.S. biotech companies fell as much as 10% premarket on Monday following reports that a top vaccine official at the U.S. Food and Drug Administration had resigned, fanning worries over slowe...
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | # Analysts |
|---|---|---|---|
| 2025 | -3.68B | Analyst x6 | |
| 2026 | -3.07B | -16.58% | Analyst x6 |
| 2027 | -2.26B | -26.30% | Analyst x4 |
| 2028 | -1.42B | -37.36% | Analyst x3 |
| 2029 | -0.83B | -41.68% | Analyst x3 |
| 2030 | -1.01B | 21.61% | Est @21.6% |
| 2031 | -1.16B | 15.74% | Est @15.7% |
| 2032 | -1.30B | 11.64% | Est @11.6% |
| 2033 | -1.41B | 8.18% | Est @8.2% |
| 2034 | -1.49B | 6.31% | Est @6.3% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2023A | -3.83B | 1.00 | -3.83B |
| 2024A | -4.06B | 1.00 | -4.06B |
| 2025E | -3.68B | 1.09 | -3.37B |
| 2026E | -3.07B | 1.19 | -2.57B |
| 2027E | -2.26B | 1.30 | -1.74B |
| 2028E | -1.42B | 1.43 | -995.06M |
| 2029E | -827.00M | 1.56 | -531.15M |
| 2030E | -1.01B | 1.70 | -591.18M |
| 2031E | -1.16B | 1.86 | -626.27M |
| 2032E | -1.30B | 2.03 | -639.91M |
| 2033E | -1.41B | 2.22 | -633.61M |
| 2034E | -1.49B | 2.42 | -616.49M |
| Terminal | -22.66B | 2.42 | -9.35B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.
